Benitec Biopharma Inc reports results for the quarter ended December 31 - Earnings Summary

Benitec Biopharma

18/02/2025 24:54

* Benitec Biopharma Inc  BNTC.OQ  reported a quarterly
adjusted
loss of 33 cents​​ per share for the quarter ended December 31,
higher than the same quarter last year, when the company
reported EPS of $-2.64.  The mean expectation of six analysts
for the quarter was for a loss of 77 cents per share. Wall
Street expected results to range from $-2.84 to -26 cents per
share.
    * Reported revenue was zero​; analysts expected zero. 
    * Benitec Biopharma Inc's reported EPS for the quarter was a
loss
of 33 cents​.
    * The company reported a quarterly loss of $7.36 million.
    * Benitec Biopharma Inc shares had fallen by 23.2% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 24.7%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 7 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "strong buy"

Wall Street's median 12-month price target for Benitec Biopharma
Inc is $28.00 
This summary was machine generated from LSEG data February 18 at
12:54 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2024      -0.77          -0.33          Beat
 Sep. 30 2024      -0.55          -0.48          Beat
 Jun. 30 2024      -0.49          -1.32          Missed
 Mar. 31 2024      -0.78          -1.64          Missed